

GLAXOSMITHKLINE PLC  
Form 6-K  
January 10, 2012

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending January 2012

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

--

Notification of Transactions of Directors, Persons Discharging  
Managerial Responsibility or Connected Persons

The Administrators of the GlaxoSmithKline Performance Share Plan notified the Company and the under-mentioned persons on 10 January 2012 of an increase in their notional interests in Ordinary shares at a price of 1482 pence per Ordinary share and ADRs at a price of \$46.13 per ADR following the notional re-investment of the dividend paid to shareholders on 5 January 2012.

	Ordinary shares	ADRs
Sir Andrew Witty	16,172.074	
Dr M M Slaoui		4,349.247
Mr S Dingemans	2,302.416	
Mr S M Bicknell	1,438.626	
Mr J M Clarke	4,026.605	
Mrs D P Connelly		2,559.470
Mr M Dunoyer	1,892.745	
Mr E J Gray	3,038.769	
Mr S A Hussain	3,973.136	
Mr W C Louv		1,312.138
Dr D Pulman		1,966.647
Mr D S Redfern	1,853.468	
Mr J R Stéphenne	2,328.843	
Ms C Thomas	2,671.731	
Mr P C Thomson	215.742	
Mr D E Troy		2,596.086
Dr P J T Vallance	2,625.312	
Ms E Walmsley	1,561.960	
	215.742	

Mrs V A  
Whyte

The notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three year measurement period.

This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte  
Company Secretary

10 January 2012

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: January 10, 2012

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc